Collect

Blood sample in an EDTA (purple-top) tube. Saliva is also acceptable.

Unacceptable Conditions

Frozen blood, blood in inappropriate tubes

Storage/Transport Temperature

Room Temp

Performed

Monday-Friday 9:00am - 4:00pm

Volume Required

3-5 ml

Minimum Required

1.5 mL

Phlebotomy Draw

Yes

Performed

Monday-Friday 9:00am - 4:00pm

Methodology

Next Generation Sequencing

Reported

28 days

Synonyms

  • Cancer Predisposition
  • HCOMP
  • ABCB11, ALK, APC, ARID5B, ATM, AXIN2, BAP1, BARD1, BLM, BMPR1A, BRCA1, BRCA2, BRIP1, BUB1B, CBL, CDC73, CDH1, CDK4, CDKN1B, CDKN1C, CDKN2A, CEBPA, CEBPE, CHEK2, COL7A1, CYLD, DDB2, DDX41, DICER1, DIS3L2, DKC1, DOCK8, EGFR, ELANE, EPCAM, ERCC2, ERCC3, ERCC4, ERCC5, ETV6, EXT1, EXT2, FAH, FANCA, FANCC, FANCG, FAS, FH, FLCN, G6PC3, GATA2, GBA, GJB2, GPC3, HABP2, HAX1, HFE, HMBS, HRAS, IKZF1, ITK, KIT, KRAS
  • MAX, MEN1, MET, MLH1, MPL, MSH2, MSH6, MTAP, MUTYH, NBN, NF1, NF2, PALB2, PAX5, PDGFRA, PHOX2B, PMS2, POLD1, POLE, POLH, PRKAR1A, PRSS1, PTCH1, PTEN, PTPN11, RAD50, RAD51C, RAD51D, RB1, RECQL4, RET, RHBDF2, RMRP, RUNX1, SBDS, SDHA, SDHAF2, SDHB, SDHC, SDHD, SERPINA1, SH2B3, SH2D1A, SLC25A13, SMAD4, SMARCA4, SMARCB1, SMARCE1, SOS1, SRY, STAT3, STK11, SUFU, TERT, TGFBR1, TMEM127, TP53, TRIM37, TSC1, TSC2, UROD, VHL, WAS, WRN, WT1, XPA, XPC

LIS Mnemonic

HCOMP

Performed By

Division of Genomic Diagnostics

Available STAT

No

Test Notes

Targeted Capture followed by Massively Parallel Sequencing. Multiplex Ligation-dependent Probe Amplification (MLPA), Real Time PCR, or Array CGH Analysis (aCGH) when needed.

Clinical Features

The CHOP Hereditary Cancer Panel utilizes next-generation sequencing technology to simultaneously analyze a panel of genes known to be associated with increased risks for a wide range of cancers. This test should be used for patients whose medical and family histories strongly suggest an underlying genetic etiology of cancer and for at risk family members. One hundred thirty genes known to be associated with cancer predisposition are analyzed using Next Generation Sequence (NGS) technology. The genes included in this panel are listed below: ABCB11, ALK, APC, ARID5B, ATM, AXIN2, BAP1, BARD1, BLM, BMPR1A, BRCA1, BRCA2, BRIP1, BUB1B, CBL, CDC73, CDH1, CDK4, CDKN1B, CDKN1C, CDKN2A, CEBPA, CEBPE, CHEK2, COL7A1, CYLD, DDB2, DDX41, DICER1, DIS3L2, DKC1, DOCK8, EGFR, ELANE, EPCAM, ERCC2, ERCC3, ERCC4, ERCC5, ETV6, EXT1, EXT2, FAH, FANCA, FANCC, FANCG, FAS, FH, FLCN, G6PC3, GATA2, GBA, GJB2, GPC3, HABP2, HAX1, HFE, HMBS, HRAS, IKZF1, ITK, KIT, MAX, MEN1, MET, MLH1, MPL, MSH2, MSH6, MTAP, MUTYH, NBN, NF1, NF2, PALB2, PAX5, PDGFRA, PHOX2B, PMS2, POLD1, POLE, POLH, PRKAR1A, PRSS1, PTCH1, PTEN, PTPN11, RAD50, RAD51C, RAD51D, RB1, RECQL4, RET, RHBDF2, RMRP, RUNX1, SBDS, SDHA, SDHAF2, SDHB, SDHC, SDHD, SERPINA1, SH2D1A, SLC25A13, SMAD4, SMARCA4, SMARCB1, SMARCE1, SOS1, SRY, STAT3, STK11, SUFU, TERT, TGFBR1, TMEM127, TP53, TRIM37, TSC1, TSC2, UROD, VHL, WAS, WRN, WT1, XPA, XPC

Molecular Testing Notes

All coding exons of the 130 genes and 20 base pairs of 5' and 3' flanking intronic sequences are analyzed. Certain known intronic mutations of these genes are also evaluated. Pathogenic/likely pathogenic variants detected by NGS are confirmed by Sanger sequencing.

CPT Codes

81455
Collection

Collect

Blood sample in an EDTA (purple-top) tube. Saliva is also acceptable.

Unacceptable Conditions

Frozen blood, blood in inappropriate tubes

Storage/Transport Temperature

Room Temp

Performed

Monday-Friday 9:00am - 4:00pm

Volume Required

3-5 ml

Minimum Required

1.5 mL

Phlebotomy Draw

Yes
Ordering

Performed

Monday-Friday 9:00am - 4:00pm

Methodology

Next Generation Sequencing

Reported

28 days

Synonyms

  • Cancer Predisposition
  • HCOMP
  • ABCB11, ALK, APC, ARID5B, ATM, AXIN2, BAP1, BARD1, BLM, BMPR1A, BRCA1, BRCA2, BRIP1, BUB1B, CBL, CDC73, CDH1, CDK4, CDKN1B, CDKN1C, CDKN2A, CEBPA, CEBPE, CHEK2, COL7A1, CYLD, DDB2, DDX41, DICER1, DIS3L2, DKC1, DOCK8, EGFR, ELANE, EPCAM, ERCC2, ERCC3, ERCC4, ERCC5, ETV6, EXT1, EXT2, FAH, FANCA, FANCC, FANCG, FAS, FH, FLCN, G6PC3, GATA2, GBA, GJB2, GPC3, HABP2, HAX1, HFE, HMBS, HRAS, IKZF1, ITK, KIT, KRAS
  • MAX, MEN1, MET, MLH1, MPL, MSH2, MSH6, MTAP, MUTYH, NBN, NF1, NF2, PALB2, PAX5, PDGFRA, PHOX2B, PMS2, POLD1, POLE, POLH, PRKAR1A, PRSS1, PTCH1, PTEN, PTPN11, RAD50, RAD51C, RAD51D, RB1, RECQL4, RET, RHBDF2, RMRP, RUNX1, SBDS, SDHA, SDHAF2, SDHB, SDHC, SDHD, SERPINA1, SH2B3, SH2D1A, SLC25A13, SMAD4, SMARCA4, SMARCB1, SMARCE1, SOS1, SRY, STAT3, STK11, SUFU, TERT, TGFBR1, TMEM127, TP53, TRIM37, TSC1, TSC2, UROD, VHL, WAS, WRN, WT1, XPA, XPC

LIS Mnemonic

HCOMP

Performed By

Division of Genomic Diagnostics

Available STAT

No

Test Notes

Targeted Capture followed by Massively Parallel Sequencing. Multiplex Ligation-dependent Probe Amplification (MLPA), Real Time PCR, or Array CGH Analysis (aCGH) when needed.

Clinical Features

The CHOP Hereditary Cancer Panel utilizes next-generation sequencing technology to simultaneously analyze a panel of genes known to be associated with increased risks for a wide range of cancers. This test should be used for patients whose medical and family histories strongly suggest an underlying genetic etiology of cancer and for at risk family members. One hundred thirty genes known to be associated with cancer predisposition are analyzed using Next Generation Sequence (NGS) technology. The genes included in this panel are listed below: ABCB11, ALK, APC, ARID5B, ATM, AXIN2, BAP1, BARD1, BLM, BMPR1A, BRCA1, BRCA2, BRIP1, BUB1B, CBL, CDC73, CDH1, CDK4, CDKN1B, CDKN1C, CDKN2A, CEBPA, CEBPE, CHEK2, COL7A1, CYLD, DDB2, DDX41, DICER1, DIS3L2, DKC1, DOCK8, EGFR, ELANE, EPCAM, ERCC2, ERCC3, ERCC4, ERCC5, ETV6, EXT1, EXT2, FAH, FANCA, FANCC, FANCG, FAS, FH, FLCN, G6PC3, GATA2, GBA, GJB2, GPC3, HABP2, HAX1, HFE, HMBS, HRAS, IKZF1, ITK, KIT, MAX, MEN1, MET, MLH1, MPL, MSH2, MSH6, MTAP, MUTYH, NBN, NF1, NF2, PALB2, PAX5, PDGFRA, PHOX2B, PMS2, POLD1, POLE, POLH, PRKAR1A, PRSS1, PTCH1, PTEN, PTPN11, RAD50, RAD51C, RAD51D, RB1, RECQL4, RET, RHBDF2, RMRP, RUNX1, SBDS, SDHA, SDHAF2, SDHB, SDHC, SDHD, SERPINA1, SH2D1A, SLC25A13, SMAD4, SMARCA4, SMARCB1, SMARCE1, SOS1, SRY, STAT3, STK11, SUFU, TERT, TGFBR1, TMEM127, TP53, TRIM37, TSC1, TSC2, UROD, VHL, WAS, WRN, WT1, XPA, XPC

Molecular Testing Notes

All coding exons of the 130 genes and 20 base pairs of 5' and 3' flanking intronic sequences are analyzed. Certain known intronic mutations of these genes are also evaluated. Pathogenic/likely pathogenic variants detected by NGS are confirmed by Sanger sequencing.
Result Interpretation
Administrative

CPT Codes

81455